Back to Search

A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy

  • Protocol Number: 202411102
  • Principal Investigator: Pachynski, Russell
  • Cancer Types: GU: Bladder, Kidney, Prostate, Testicular

Learn more about this study at: clinicaltrials.gov

For more information on this trial, contact us here:

Phone
800-600-3606
Email
[email protected]

Brief Summary

The main objective of the study is to compare overall survival in participants receiving xaluritamig versus investigator’s choice (cabazitaxel or second androgen receptor-directed therapy [ARDT]).

Protocol Interventions

Drug: Abiraterone, Drug: Enzalutamide, Drug: Cabazitaxel